Adrenal Cortex Cancer

Mitotane, sold under the brand name Lysodren, is a steroidogenesis inhibitor and cytostatic antineoplastic medication which is used in the treatment of adrenocortical carcinoma and Cushing’s syndrome. It is a derivative of the early insecticide DDT and an isomer of p,p’-DDD (4,4′-dichlorodiphenyldichloroethane) and is also known as 2,4′-(dichlorodiphenyl)-2,2-dichloroethane (o,p’-DDD). An anticancer drug used in treating adrenocortical cancer and ACTH-producing pituitary tumors (Cushing disease). Mitotane Tablet –

Mitotane has been produced by Bristol Myers Squibb but it is marketed as an orphan drug for adrenocortical carcinoma due to the small number of patients in need of it. Its main use is in those patients who have persistent disease despite surgical resection, those who are not surgical candidates, or those who have metastatic disease.

A drug used to treat high levels of uric acid in the blood of adults and children with leukemia, lymphoma, or other types of cancer who are receiving certain types of anticancer therapy. Uric acid is a natural substance that can build up in the blood as tumors break down. Rasburicase helps break down and remove uric acid from the body. It is a type of recombinant enzyme and a type of urate-lowering drug. Also called Elitek and recombinant urate oxidase.

Rasburicase is approved for use by the U.S. Food and Drug Administration (and European counterparts) for the prevention and treatment of tumor lysis syndrome (TLS) in people receiving chemotherapy for hematologic cancers such as leukemias and lymphomas. However, it is not clear if it results in important benefits such as decreased kidney problems or decreased risk of death as of 2017.

Rasburicase is approved to treat adults and children with:

High levels of uric acid in the blood.